Glaukos.
public company
- Reports this week
- 0
- Active events
- 0
- Connections
- 39
What's happening
Earlier this month
-
Citigroup raised its price target and gave a buy rating for Glaukos, while Leana Wen sold Glaukos stock.Some support3 reports
-
MarketBeat's stock screener tool highlights Glaukos, Boston Scientific, and Stryker Corporation as medical stocks to watch.Some support1 report
-
Glaukos revenue and Textron earnings both surpassed FactSet estimates on October 29, 2026.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
Glaukos Corporation increased its holdings in its own stock.Some support1 report
-
Glaukos filed reports with the SEC regarding its stock holdings on August 6, 2026.Some support1 report
-
Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.Well supported6 reports
-
Glaukos CFO Alex R. Thurman sold shares of the company's stock.Some support1 report
-
Analyst firm assumed coverage on Glaukos shares.Some support1 report
-
Thomas Burns was appointed CEO and chairman of Glaukos, noting that EU certification is key to maintaining the company's presence in Europe.Some support5 reports
-
Glaukos shares underperformed the S&P 500 on July 31, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Glaukos this week
News at the entities that move Glaukos most-
FDA StructuralFDA announced a dangerous contaminant in sandwiches from Grand Strand Sandwich Company sold in Virginia, North Carolina, and South Carolina.Moves Glaukos
-
Royal Bank of Canada TransactionalRBC launched a monitoring service tracking economic trends in Caribbean economies including Aruba and Barbados.Moves Glaukos
-
Citigroup Mentioned togetherJPMorgan Chase, Bank of America, Wells Fargo, and Citigroup are competing for investor capital.Moves Glaukos
-
curry OperationalCurry reported to the Church Council on sustainability.Moves Glaukos
-
SEC StructuralA new Italian license impacts revenue for a company, per a November 2026 report.Moves Glaukos
-
FactSet OperationalJetBlue faces higher fuel costs, FactSet data rates Campbell's stock, and Clorox is among Wall Street's most hated stocks.Moves Glaukos
Connections
The 16 strongest of 39, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Tom Burns Structural
Tom Burns holds the formal leadership roles of Chairman and CEO of Glaukos.
-
Thomas Burns Structural
Thomas Burns serves as the Chairman and CEO of Glaukos.
-
FDA Structural
Glaukos's ability to market its products is dependent on receiving formal approval from the FDA.
-
Chris Lewis Structural
Chris Lewis serves as VP of Investor Relations for Glaukos.
-
SEC Structural
Glaukos is subject to regulatory oversight by the SEC regarding its stock holdings and required filings.
-
Needham & Company Mentioned together
Needham & Company provides analyst coverage and price targets for Glaukos shares.
-
Royal Bank of Canada Transactional
Royal Bank of Canada has increased its holdings in Glaukos Corporation stock.
-
curry Operational
Curry and Glaukos collaborated on a joint awareness campaign.
Show all 16 connections
-
FactSet Operational
Glaukos's revenue performance is tracked and compared against consensus estimates provided by FactSet.
-
Citigroup Mentioned together
Citigroup provides investment ratings and price targets for Glaukos.
-
Stryker Corporation Mentioned together
Stryker Corporation and Glaukos are grouped thematically as medical stocks to watch.
-
Aliso Viejo Shared context
The company is located in Aliso Viejo, California.
-
Boston Scientific Mentioned together
Both companies are grouped thematically as medical stocks to watch.
-
MarketBeat Mentioned together
MarketBeat features and provides consensus ratings for Glaukos as part of its financial analysis service.
-
Abbott Laboratories Operational
Both Abbott Laboratories and Glaukos actively compete within the medical device stock market.
-
Leana Wen Transactional
Leana Wen sold shares of Glaukos stock.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsAugust 2026
2 eventsShow 2 earlier months
July 2026
3 eventsJune 2026
3 events- Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.
- Thomas Burns was appointed CEO and chairman of Glaukos, noting that EU certification is key to maintaining the company's presence in Europe.
- Glaukos shares underperformed the S&P 500 on July 31, 2025.